


# Substance Use and Older People



**Edited by**  
Ilana Crome  
Li-Tzy Wu  
Rahul (Tony) Rao  
Peter Crome

**WILEY** Blackwell

Addiction **Press**

# CONTENTS

[COVER](#)

[SERIES PAGE](#)

[TITLE PAGE](#)

[COPYRIGHT PAGE](#)

[DEDICATION](#)

[CONTRIBUTORS](#)

[FOREWORD](#)

[INTRODUCTION](#)

[References](#)

[LIST OF ABBREVIATIONS](#)

[Section 1: LEGAL AND ETHICAL ASPECTS OF CARE  
FOR OLDER PEOPLE WITH SUBSTANCE MISUSE](#)

[Chapter 1: NEGOTIATING CAPACITY AND CONSENT  
IN SUBSTANCE MISUSE](#)

[Introduction](#)

[Capacity and unwise decisions](#)

[Consent, barriers to decision making and  
substituted decision making](#)

[Conclusion](#)

[References](#)

[Chapter 2: ELDER ABUSE](#)

[Introduction](#)

[Defining elder abuse](#)

[Main reviews](#)

[The effects of elder abuse](#)

[Discussion](#)

Conclusions and next steps

References

### Chapter 3: THE UNITED STATES PERSPECTIVE

The ageing of the baby boomers and its impact on substance abuse

Ethical and legal aspects of substance misuse in older adults

Conclusion

References

### Chapter 4: THE EUROPEAN PERSPECTIVE

Introduction

Use and possession

Crime

European Convention of Human Rights

Delivering services for the elderly with substance misuse - ethical aspects

Research and development

Policy making

Some differences between Europe and the USA

Ethical issues regarding treatment

Stigma

Underprescribing controlled drugs

Summary

References

### Chapter 5: CLINICAL MEDICINE AND SUBSTANCE MISUSE

Introduction

Why is clinical medicine important?

Challenges for the future

[Conclusions](#)

[References](#)

[Section 2: EPIDEMIOLOGY AND DEMOGRAPHY](#)

[Chapter 6: CIGARETTE SMOKING AMONG ADULTS  
AGED 45 AND OLDER IN THE UNITED STATES,  
2002-2011](#)

[Introduction](#)

[Evaluation methodology](#)

[Results](#)

[Discussion](#)

[Conclusion](#)

[References](#)

[Chapter 7: EPIDEMIOLOGY AND DEMOGRAPHY OF  
ALCOHOL AND THE OLDER PERSON](#)

[Introduction](#)

[Main reviews](#)

[Discussion](#)

[Conclusions and next steps](#)

[References](#)

[Chapter 8: EPIDEMIOLOGY AND DEMOGRAPHY OF  
ILLICIT DRUG USE AND DRUG USE DISORDERS  
AMONG ADULTS AGED 50 AND OLDER](#)

[Introduction](#)

[Survey studies](#)

[Studies of treatment-seeking or clinical patients](#)

[Health implications](#)

[Discussion](#)

[Next steps](#)

[References](#)

## Chapter 9: EPIDEMIOLOGY AND DEMOGRAPHY OF NONMEDICAL PRESCRIPTION DRUG USE

Introduction

Findings

Discussion

Conclusions

Acknowledgement

References

## Section 3: LONGITUDINAL STUDIES OF AGEING AND SUBSTANCE ABUSE

### Chapter 10: AGEING AND THE DEVELOPMENT OF ALCOHOL USE AND MISUSE

Background

Results

Discussion

Conclusions

References

### Chapter 11: PROGRESSION FROM SUBSTANCE USE TO THE DEVELOPMENT OF SUBSTANCE USE DISORDERS

Introduction

Substance use progression process

Risk factors influencing substance use progression

Future direction

Conclusions

Acknowledgement

References

### Chapter 12 : PSYCHOPHARMACOLOGY AND THE CONSEQUENCES OF ALCOHOL AND DRUG INTERACTIONS

[The extent of alcohol and drug misuse among older adults](#)

[Psychopharmacology of alcohol and drug misuse in older people](#)

[Alcohol-drug interactions in older adults](#)

[Clinical presentation and evaluation of substance use disorders in the elderly](#)

[Conclusions](#)

[References](#)

#### [Section 4: COMPREHENSIVE GERIATRIC ASSESSMENT AND SPECIAL NEEDS OF OLDER PEOPLE](#)

##### [Chapter 13: COMPREHENSIVE GERIATRIC ASSESSMENT AND THE SPECIAL NEEDS OF OLDER PEOPLE](#)

[Background](#)

[Assessment](#)

[Case presentations](#)

[Discussion](#)

[Conclusion](#)

[References](#)

#### [Section 5: SCREENING AND INTERVENTION IN HEALTH CARE SETTINGS](#)

##### [Chapter 14: SCREENING AND BRIEF INTERVENTION IN THE PSYCHIATRIC SETTING](#)

[Overview](#)

[Screening and assessment for alcohol use disorders](#)

[Illicit drugs](#)

[Prescription drug abuse](#)

[Brief intervention for alcohol, prescription drug abuse and illegal drug use](#)

[Summary](#)

[References](#)

## [Chapter 15: TOBACCO USE CESSATION](#)

[Introduction](#)

[Smoking cessation interventions among older adults](#)

[Counselling and behavioural interventions](#)

[Physician-delivered interventions](#)

[Other interventions](#)

[Conclusions](#)

[References](#)

## [Section 6: USE OF SUBSTANCE ABUSE TREATMENT SERVICES AMONG OLDER ADULTS](#)

### [Chapter 16 : EPIDEMIOLOGY OF USE OF TREATMENT SERVICES FOR SUBSTANCE USE PROBLEMS](#)

[Introduction](#)

[Tobacco cessation service use and characteristics](#)

[Alcohol treatment use and characteristics](#)

[Trend in substance abuse treatment admissions](#)

[Drug abuse treatment use and outcomes](#)

[Substance abuse treatment in general health care settings](#)

[Discussion and conclusion](#)

[References](#)

## [Chapter 17: IMPLICATIONS FOR PRIMARY CARE](#)

[Background](#)

[Implications for primary care](#)

[Different populations at risk](#)

[Screening in primary care](#)

[Scale of benefit](#)

[Co-morbidities and social context](#)

[Conclusions](#)

[References](#)

## [Chapter 18: ADDICTION LIAISON SERVICES](#)

[Introduction](#)

[Organizing an addiction liaison service to a general hospital](#)

[Case vignette 1](#)

[Addiction liaison services for older adults](#)

[Essential elements of liaison service provision for older adults](#)

[Screening for alcohol problems in older adults](#)

[Screening for drug use problems](#)

[Case vignette 2](#)

[Summary](#)

[References](#)

## [Chapter 19: CURRENT HEALTHCARE MODELS AND CLINICAL PRACTICES](#)

[Introduction](#)

[An ageing population](#)

[Service development and provision](#)

[Integrated care and workforce development](#)

[Conclusions and recommendations](#)

[References](#)

## [Section 7: AGE-SPECIFIC TREATMENT INTERVENTIONS AND OUTCOMES](#)

## Chapter 20: PHARMACOLOGICAL AND INTEGRATED TREATMENTS IN OLDER ADULTS WITH SUBSTANCE USE DISORDERS

Introduction

Tobacco

Alcohol

Opioids

Benzodiazepines

Other substances of abuse

Integrated treatments

Conclusion and future directions

References

## Chapter 21: THE ASSESSMENT AND PREVENTION OF POTENTIALLY INAPPROPRIATE PRESCRIBING

Introduction

Inappropriate psychotropic use in elderly patients

Implicit IP criteria

Explicit IP criteria

Applying STOPP/START criteria as an intervention

Other methods of detection and prevention of IP in older people

Conclusions

References

## Chapter 22: AGE-SENSITIVE PSYCHOSOCIAL TREATMENT FOR OLDER ADULTS WITH SUBSTANCE ABUSE

Introduction

Seven characteristics of age-sensitive treatment

2 - Flexible

[Six components of age-sensitive psychosocial treatment](#)

[Age-segregated or mixed-age treatment](#)

[Future directions](#)

[Acknowledgements](#)

[References](#)

## [Chapter 23: INTEGRATED TREATMENT MODELS FOR CO-MORBID DISORDERS](#)

[Introduction](#)

[Methodological approach to examining SMCD in older people](#)

[Future direction and challenges](#)

[References](#)

## [Section 8: POLICY: PROPOSALS FOR DEVELOPMENT](#)

### [Chapter 24: PROPOSALS FOR POLICY DEVELOPMENT](#)

[Introduction](#)

[Recognition of a need or problem and arguments made to justify the development of policy.](#)

[Policy options](#)

[Policy design and implementation](#)

[Conclusion](#)

[References](#)

### [Chapter 25: PROPOSALS FOR ALCOHOL-RELATED POLICY DEVELOPMENT IN THE UNITED STATES](#)

[Recommended low-risk alcohol consumption levels](#)

[Traffic crash risks among the elderly.](#)

[Driving policy questions](#)

[Factors to consider when contemplating legal policies](#)

[Summary and conclusions](#)

[References](#)

[Chapter 26: PROPOSALS FOR POLICY DEVELOPMENT](#)

[Introduction](#)

[Past and present approaches to reduce tobacco consumption](#)

[Phase three anti-tobacco efforts](#)

[Recent anti-tobacco proposals](#)

[Policy proposals to further reduce tobacco prevalence](#)

[References](#)

[Chapter 27: RECOMMENDATIONS](#)

[Background](#)

[Epidemiology](#)

[Clinical presentations](#)

[Education and training](#)

[Who gets treatment - treatment interventions](#)

[Concluding remarks](#)

[INDEX](#)

[END USER LICENSE AGREEMENT](#)

## **List of Tables**

Chapter 03

[Table 3.1 Elements of decisional capacity with clinical examples](#)

Chapter 06

[Table 6.1 Overall characteristics of US adults aged 45 years or older \(US National Health Interview Survey, 2002 and 2011\).](#)

[Table 6.2 Current cigarette smoking among US adults aged 45 years or older by selected sociodemographic characteristics \(US National Health Interview Survey, 2002 and 2011\).](#)

[Table 6.3 Adjusted odds ratios \(AOR\) of correlates of current cigarette smoking among US adults aged 45 years or older by age strata and by year \(US National Health Interview Survey, 2002 and 2011\).](#)

## Chapter 07

[Table 7.1 Various criteria for heavy, hazardous or at-risk drinking.](#)

## Chapter 08

[Table 8.1 Studies of illicit drug use](#)

## Chapter 09

[Table 9.1 Characteristics of past-year users aged 50 and older: NSDUH 2011 \[9\]](#)

[Table 9.2 Characteristics of emergency department patients aged 55 and over: DAWN 2010 \[11\]](#)

[Table 9.3 Characteristics of treatment admissions aged 55 and older: TEDS 2010 \[14\]](#)

[Table 9.4 Drug poisoning deaths per 100 000 aged 55-64: CDC 2010 \[13\]](#)

## Chapter 10

[Table 10.1 Drinking patterns by sex and World Health Organization region \(all ages\).](#)

## Chapter 11

[Table 11.1 Influences on substance use and the progression of substance use to disorders](#)

[Table 11.2 Typical symptoms of drug use progression among the elderly](#)

## Chapter 12

[Table 12.1 Physical and psychiatric symptoms or signs that trigger evaluation for substance use disorders in the elderly](#)

[Table 12.2 Clinical evaluation of substance use disorders in the elderly](#)

## Chapter 13

[Table 13.1 Diagnostic and statistical manual criteria for substance use disorder \(SUD\)](#)

## Chapter 15

[Table 15.1 Multimodal interventions for older smokers: A review of randomized trials](#)

## Chapter 16

[Table 16.1 Prevalences of substance use among older adults in the United States](#)

[Table 16.2 Studies of tobacco treatment among older adults](#)

[Table 16.3 Studies of alcohol treatment use among older adults](#)

[Table 16.4 Studies of alcohol and drug abuse treatment use among older adults](#)

## Chapter 21

[Table 21.1 Prevalence rates of potentially inappropriate medications \(PIMs\) in older patient](#)

[groups in various clinical settings according to STOPP criteria and Beers \[2\]](#)

[Table 21.2 Prevalence rates of potential prescribing omissions \(PPOs\) in older patient groups in various clinical settings \[2\]](#)

[Table 21.3 Results of a randomized controlled trial \(Figure 21.2\) comparing the adverse drug reaction \(ADR\) rates in older people with acute illness receiving either standard pharmaceutical care \(control\) or adjustment of their medication according to STOPP/START criteria advice offered to their attending doctors at a single time point early in the index hospitalization \(intervention\) \[38\]](#)

## Chapter 26

[Table 26.1 Overview of four phases of tobacco control in the United States from 1950 to 2013](#)

[Table 26.2 Phases of litigation against the tobacco industry from 1954 to 2013](#)

# List of Illustrations

## Chapter 06

[Figure 6.1 Ten-year trends in the proportion \(%\) of US adults aged 45-64 years and 65+ years \(US National Health Interview Survey, 2002-2011\).](#)

[Figure 6.2 Ten-year trends in current cigarette smoking prevalence \(%\) among US adults aged 45-64 years and  \$\geq 65\$  years \(US National Health Interview Survey, 2002-2011\).](#)

[Figure 6.3 Ten-year trends in 'some day' and 'everyday' cigarette smoking prevalence \(%\) in the past month among US adults aged 45-64 years and](#)

65+ years (US National Health Interview Survey, 2002-2011).

## Chapter 07

Figure 7.1 Any alcohol use in the past 30 days: US population all ages.

Figure 7.2 Average number of drinks per day for age groups compared to the CDC heavy drinking criterion.

Figure 7.3 Percentage of men and women aged 65 or older who within the last 30 days drank more than the indicated number of drinks per day.

## Chapter 09

Figure 9.1 Lifetime, past-year and past-month nonmedical use of pain relievers: NSDUH 2011 [1].  
Notes : Nonmedical use is defined as use of a medication without a prescription belonging to the respondent or use that occurred simply for the experience or feeling the drug caused. Pain relievers include hydrocodone, methadone, morphine, oxycodone, tramadol and similar drugs.

Figure 9.2 Change in rates for emergency department patients: DAWN 2004-2011 [9].

Figure 9.3 Proportion of treatment admissions aged 45 and over with primary problems with other opiates and synthetics: TEDS 1992-2010 [13]. Note : Other opiates and synthetics include buprenorphine, codeine, hydrocodone, hydromorphone, meperidine, morphine, opium, oxycodone, pentazocine, propoxyphene, tramadol and any other drug with morphine-like effects.

Figure 9.4 Drug poisoning death rates by age: United States, 1999-2010 [17].

Figure 9.5 Drug poisoning death rates by age group: NCHS 2010 [13]. Note : The International Classification of Diseases-10 definition of natural and semi-synthetic opioid analgesics includes morphine, oxycodone, and hydrocodone. Synthetic opioid analgesics include fentanyl.

## Chapter 11

Figure 11.1 Psychoactive substance use spectrum.

Figure 11.2 Framework of progression from substance use to substance use disorders.

## Chapter 21

Figure 21.1a Effect of application of STOPP criteria within 48 hours of acute hospital admission (intervention) on medication appropriateness (MAI score) in older patients compared to normal pharmaceutical care (control). The highly significant improvement in group mean MAI score in the intervention group was rapid and was maintained to the end of a six-month follow-up interval (medication appropriateness improves as MAI score decreases). [37].

Figure 21.1b Effect of application of START criteria shortly after hospital admission in acutely ill older people. Over one-third of patients had at least one potential prescribing omission according to Assessment of Underutilization of Medication (AUM) criteria. After application of START criteria, the inappropriate underutilization of medication rate in the intervention group fell to under 3%; this beneficial effect was maintained to the end of six-months' follow-up [37].

Figure 21.2 Schematic diagram of a randomized controlled trial of STOPP/START criteria as an

intervention in older people who are hospitalized with acute unselected illness. The aim was to determine if application of STOPP/START criteria at a single time point early in the hospital stay could significantly attenuate adverse drug reactions (ADRs) during the index hospitalization.

Addiction Press aims to communicate current ideas and evidence in this expanding field, not only to researchers and practising health professionals, but also to policy makers, students and interested non-specialists. These publications are designed to address the significant challenges that addiction presents to modern society.

**Other books in the Addiction Press series**

*Understanding Hard to Maintain Behaviour Change:  
A Dual Process Approach*

Ron Borland  
9781118572931

*Theory of Addiction*

Robert West and Jamie Brown  
9780470674215

*Clinical Handbook of Adolescent Addiction*

Edited by R. Rosner  
9780470972342

*Harm Reduction in Substance Use and High-Risk Behaviour*

Edited by R. Pates & D. Riley  
9781405182973

*Neuroimaging in Addiction*

Edited by B. Adinoff & E. Stein  
9780470660140

*Injecting Illicit Drugs*

Edited by R. Pates, A. McBride & K. Arnold  
9781405113601

*Treating Drinkers and Drug Users in the Community*

T. Waller & D. Rumball  
9780632035755

*Addiction: Evolution of a Specialist Field*

Edited by G. Edwards

9780632059768

# **Substance Use and Older People**

*Edited by*

**Ilana Crome, MA MD MPhil FRCPsych**

**Li-Tzy Wu, ScD MA**

**Rahul (Tony) Rao, MD MSc FRCPsych**

**Peter Crome, MD PhD DSc FRCP FFPM  
FBPharmacolS**

**WILEY Blackwell**

This edition first published 2015 © 2015 by John Wiley & Sons, Ltd

*Registered Office*

John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

*Editorial Offices*

9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

1606 Golden Aspen Drive, Suites 103 and 104, Ames, Iowa 50010, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wiley-blackwell](http://www.wiley.com/wiley-blackwell)

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should

be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

*Library of Congress Cataloging-in-Publication Data*

Substance use and older people / edited by Ilana Crome, Li-Tzy Wu, Rahul (Tony) Rao, Peter Crome.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-119-97538-0 (cloth)

I. Crome, Ilana B., editor. II. Wu, Li-Tzy., editor. III. Crome, Peter, editor. IV. Rao, Rahul, editor.

[DNLM: 1. Substance-Related Disorders. 2. Aged. 3. Middle Aged. WM 270]

HV5824.A33

362.29084'9-dc23

2014020561

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

*This book is dedicated to our families - past, present and future.*

# CONTRIBUTORS

## **Marja Aartsen, PhD**

Assistant Professor Sociology and Social Gerontology,  
Faculty of Social Sciences, VU University Amsterdam,  
Amsterdam, The Netherlands

## **Mohammed Abou-Saleh, MPhil FRCPsych**

Professor of Psychiatry, St George's, University of London,  
London, UK

## **Stephan Arndt, PhD**

Director, Iowa Consortium for Substance Abuse Research;  
Professor, Departments of Psychiatry and Biostatistics,  
University of Iowa, Iowa City, IA, USA

## **Amit Arora, MD FRCP MSc**

Consultant Physician and Geriatrician, University Hospital  
of North Staffordshire, Stoke-on-Trent, UK; Honorary  
Clinical Lecturer, Keele University, Keele, UK

## **Roger Bloor, MD MPsyMed FRCPsych Cert Med Ed**

Consultant in Addiction Psychiatry, North Staffordshire  
Combined Healthcare NHS Trust, Teaching Fellow, School  
of Medicine, Keele University, Keele, UK

## **Kathleen T. Brady, MD PhD**

Associate Provost of Clinical and Translational Research,  
and Director of South Carolina Clinical and Translational  
Research Institute, Medical University of South Carolina,  
Charleston, SC, USA

## **Penny L. Brennan, PhD**

Research Health Science Specialist, Center for Health Care  
Evaluation, Veterans Affairs Palo Alto Health Care System,  
Menlo Park CA, USA

**Shawna L. Carroll Chapman, PhD**

Postdoctoral Researcher, Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University Medical Center, Durham, NC, USA

**Devoshree Chatterjee, MRCP**

Department of Primary Care & Population Health, University College London, London, UK

**Marion Coe, BA**

Intramural Research Training Award Fellow, Section on Human Psychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA

**Ilana B. Crome, MA MD MPhil FRCPsych**

Senior Research Fellow, Imperial College, London, UK

Emeritus Professor of Addiction Psychiatry, Keele University, Keele, UK

Honorary Consultant Psychiatrist, South Staffordshire and Shropshire Healthcare NHS Foundation Trust, Stafford, UK

Honorary Professor, Queen Mary University of London, London, UK

**Peter Crome, MD PhD DSc FRCP FFPM  
FBPharmacols**

Honorary Professor, Department of Primary Care and Population Health, University College London, London, UK

Emeritus Professor of Geriatric Medicine, Keele University, Keele, UK

**Shanta R. Dube, PhD MPH**

Associate Professor, Division of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, GA, USA

**Michael Fleming, MD MPH**

Professor, Department of Psychiatry and Family Medicine,

Northwestern University, Chicago, IL, USA

**Cynthia M.A. Geppert, MD MA PhD MPH MSBE**

Chief, Consultation Psychiatry and Ethics, New Mexico Veterans Affairs Health Care System, Albuquerque, NM, USA

Associate Professor of Psychiatry and Director of Ethics Education, University of New Mexico School of Medicine, Albuquerque, NM, USA

**Michael Givel, PhD**

Professor, Department of Political Science, The University of Oklahoma, Norman, OK, USA

**Kerry M. Green, PhD**

Assistant Professor, Department of Behavioral and Community Health, University of Maryland School of Public Health, College Park, MD, USA

**Ralph Hingson, ScD MPH**

Director, Division of Epidemiology and Prevention Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA

**Steve Iliffe, FRCGP**

Professor of Primary Care for Older People, Department of Primary Care & Population Health, University College London, London, UK

**Stephen Jackson, MD FRCP**

Professor of Clinical Gerontology, King's College Hospital, London, UK

**Jonathan C. Lee, MD**

Associate Medical Director, The Farley Center at Williamsburg Place, Williamsburg, VA, USA

Assistant Professor, Department of Psychiatric Medicine, Brody School of Medicine, East Carolina University, NC, UK

**Sonne Lemke, PhD**

Health Science Specialist, Program Evaluation and Resource Center, Department of Veteran Affairs, Menlo Park, CA, USA

**Ting-Kai Li, MD**

Professor, Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University Medical Center, Durham, NC, USA

**Susanne MacGregor, MA PhD FRSA FAcSS**

Professor of Social Policy, Department of Social and Environmental Health Research, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, University of London, London, UK

**Paolo Mannelli, MD**

Associate Professor, Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University Medical Center, Durham, NC, USA

**Jill Manthorpe, MA**

Professor of Social Work, Director of the Social Care Workforce Research Unit, King's College London, London, UK

**Finbarr C. Martin, MD MSc FRCP FCST**

Consultant Geriatrician at Guys & St Thomas' NHS Foundation Trust, London, UK  
Honorary Professor of Medical Gerontology, King's College London, London, UK

**Jane Carlisle Maxwell, PhD**

Senior Research Scientist, Addiction Research Institute, Center for Social Work Research, The University of Texas at Austin, Austin, TX, USA

**Maitreyee Mohanty, PhD**

Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA

**Rudolf H. Moos, PhD**

Professor Emeritus, Stanford University; Center for Health Care Evaluation, Veterans Affairs Palo Alto Health Care System, Menlo Park, CA, USA

**Denis O'Mahony, MD FRCPI FRCP**

Department of Medicine (Geriatrics), University College Cork, Cork, Ireland

**Andrew O'Neill, MB BaO BCh MRCP**

Specialist Registrar in Geriatric Medicine, University Hospital of North Staffordshire, Stoke-on-Trent, UK

**Ashwin A. Patkar, MD MRC Psych**

Professor, Department of Psychiatry and Behavioral Sciences, Department of Community and Family Medicine, Medical Director, Duke Addiction Programs & Center for Addictive Behavior and Change, School of Medicine, Duke University Medical Center, Durham, NC, USA

**Daniel J. Pilowsky, MD MPH**

Assistant Professor of Clinical Epidemiology and Psychiatry, Department of Epidemiology, Mailman School of Public Health; and Department of Psychiatry, Columbia College of Physicians and Surgeons, Columbia University, New York, NY, USA

**Vijay A. Ramchandani, PhD**

Investigator and Chief, Section on Human Psychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA

**Rahul (Tony) Rao, MD MSc FRCPsych**

Visiting Researcher, Department of Old Age Psychiatry, Institute of Psychiatry, London, UK and Lead for Dual Diagnosis, Mental Health of Older Adults and Dementia

Clinical Academic Group, South London and Maudsley NHS Foundation Trust, UK

**Kritika Samsi, MSc PhD**

Research Fellow, Social Care Workforce Research Unit, King's College London, UK

**Abdi Sanati, MD MSc MRCPsych**

Consultant psychiatrist, North East London NHS Foundation Trust, London, UK

**Susan K. Schultz, MD**

Professor, University of Iowa College of Medicine, Iowa City, IA, USA

**Kathleen Schutte, PhD**

Research Health Science Specialist, Center for Health Care Evaluation, Veterans Affairs Palo Alto Health Care System, Menlo Park CA, USA

**M. Shafi Siddiqui, MD**

Linden Oaks Medical Group, Naperville, IL, USA

**Patricia W. Slattum, PharmD PhD**

Director, Geriatric Pharmacotherapy Program, Professor of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA

**Carla L. Storr, MPH ScD**

Professor, Department of Family & Community Health, University of Maryland School of Nursing, Baltimore, MD, USA

**Peter J. Taylor, DO MA**

Consulting Geropsychiatrist New Mexico Veterans Affairs Health Care System, Albuquerque, New Mexico, USA

**Derrett Watts, MBBCh DRCOG MRCPsych MPhil**

Consultant Psychiatrist - Substance Misuse, North Staffordshire Combined Healthcare NHS Trust, Stoke-on-Trent, UK

**Dan Wilson, MB BChir MRCP**

Department of Clinical Gerontology, King's College Hospital  
NHS Foundation Trust, London, UK

**Li-Tzy Wu, ScD MA**

Professor of Psychiatry, Department of Psychiatry and  
Behavioral Sciences, School of Medicine, Duke University  
Medical Center, Durham, NC, USA